TRACK(S): CRS, GEN, INT, ONC
Moderator: Michael I. D’Angelica, MD, FACS, New York, NY
Co-Moderator: Konstantin Umanskiy, MD, FACS, Chicago, IL
The goal of this session is to have a panel of U.S. and international surgeons and oncologists discuss the international and U.S. experience regarding the different strategies of managing patients with colorectal cancer and hepatic metastasis. Specifically, the three main strategies are colorectal cancer and chemotherapy and liver resection; synchronous colorectal cancer and hepatic metastases resection; and chemotherapy liver metastasis resection and colorectal cancer. The goal is to identify what strategy is better for what patient.
Presentations and Speakers
Neoadjuvant Chemotherapy for Resectable Synchronous Metastatic Colorectal Cancer: Is There a Benefit?
Matthew J. Weiss, MD, FACS, Baltimore, MD
Should We Resect an Asymptomatic Rectal Cancer Primaryin Metastatic Rectal Cancer?
Najjia N. Mahmoud, MD, FACS, FASCRS, Philadelphia, PA
Locally Advanced Rectal Cancer and Synchronous Resectable Hepatic Metastases: What Is the Timing and Priority of Hepatic Resection?
Brendan C. Visser, MD, FACS, Stanford, CA
Total Mesorectal Excision (Low Anterior Resection or Abdominoperineal Resection) at the Time of Hepatic Resection for Colorectal Metatsases: Pros and Cons
James Yoo, MD, FACS, FASCRS, Boston, MA